Get Confirmmdxtestrequisitionform

ConfirmMDx is a molecular test clinically validated for detection of prostate cancer (PCa) in tissue from PCa-negative biopsies. In this clinical utility study, we evaluated the impact of ConfirmMDx on the management of patients being considered for repeat prostate biopsy in a community urology practice.

Confirm mdx for Prostate Cancer works at the DNA level to help identify undetected cancers. The test is able to detect abnormal DNA changes associated with the presence of prostate cancer. These changes cannot be seen by the standard microscopic evaluation traditionally used by pathologists to screen prostate biopsies.

The sensitivity of The EPI Test is 92%. The sensitivity measures the proportion of actual GS7 and above that are correctly identified as positive.

The MyVisit fee is $80 per person. Book your appointment online here.

A prostate biopsy is one of the most accurate ways to diagnose prostate cancer. But because it is an invasive procedure, other screening methods are used first. Some tests may be carried out by your GP when you first go to them with concerns.

ConfirmMDX is not yet FDA approved but is in use as a supplement to traditional diagnostic such as a biopsy.

Confirm mdx for Prostate Cancer works at the DNA level to help identify undetected cancers. The test is able to detect abnormal DNA changes associated with the presence of prostate cancer. These changes cannot be seen by the standard microscopic evaluation traditionally used by pathologists to screen prostate biopsies.

The retail price for the epigenetic assay is $206 per individual core, or $2061 for a 10-core biopsy (pricing is based on the cost of the ConfirmMDx for Prostate Cancer Test, as provided by MDxHealth, the manufacturer of this test).